CagriSema Dosing Schedule: The Verified 16-Week Trial Chart

Affiliate disclosure: We don't sell CagriSema. No FDA-approved commercial CagriSema product exists. One link on this page (Ro) is a paid partner link, and we may earn a commission if you use it. It changes nothing about the facts below or the order we put them in.

The CagriSema dosing schedule used in the main trial started at 0.25 mg of cagrilintide plus 0.25 mg of semaglutide, once a week. Both went up every four weeks — 0.5, then 1.0, then 1.7 — reaching 2.4 mg of each after a 16-week climb. As of August 8, 2026, that's a clinical trial protocol, not an FDA-approved prescription.

So that's the chart. Here's the part almost nobody tells you: 42.6% of people were not on the top dose at week 68. And the people who ended up lower actually lost more weight.

That's not a typo, and it's not a reason to take less. It's the most useful thing in this drug's entire dosing story, and it takes one number from Novo Nordisk's own investor slides to explain. We'll get there.

The CagriSema dosing schedule used in REDEFINE 1. One shot a week, under the skin. Both drugs went up together. Sources: the published REDEFINE 1 report and ClinicalTrials.gov record NCT05567796. This is not a patient dosing instruction.

Read this if: you found two charts that don't match, you want to know whether everyone in the trial had to reach 2.4 mg/2.4 mg, or you're deciding whether to wait for this drug.

This page can't tell you: what dose is right for you, how to measure anything from a vial, how many units to draw, whether to move up or down, or what to do if you miss a shot. There's no approved CagriSema label yet, so nobody can honestly give you official patient instructions.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

What we actually verified

• The exact dose steps in the main Phase 3 trial
• The four-week gap between steps and the 16-week climb
• That trial doctors could delay an increase or lower a person's dose
• That 74.7% reached the top dose at some point and 57.4% were on it at week 68
• The number, timing, weight loss, BMI, and recent gut-event pattern around dose reductions in Novo's 2026 follow-up analysis
• Side-effect and discontinuation rates across all four REDEFINE 1 groups
• That there is still no FDA-approved CagriSema label
• Novo's current expectation of a U.S. decision in the fourth quarter of 2026
• FDA's statement that cagrilintide cannot be used in compounding under federal law
• Four CagriSema dose pairs now studied in Phase 3: 1.0/1.0, 1.7/1.7, 2.4/2.4, and 2.4/7.2
• Ro's live membership and medication prices, checked against Ro and, where possible, the manufacturer on August 8, 2026

Still unknown: the final approved schedule, official CagriSema missed-dose rules, the commercial device, CagriSema's price, insurance coverage, and a launch date. We'd rather list those than guess at them.

What is the CagriSema dosing schedule?

CagriSema is one weekly shot under the skin that holds two drugs in fixed amounts. In the main Phase 3 trial, people started at 0.25 mg of each drug and moved up one step every four weeks — 0.5, then 1.0, then 1.7 — reaching 2.4 mg of each after a 16-week climb. Both drugs rose together because they were delivered as one fixed-dose combination.

Let's slow that down, because two small things trip people up.

What the two numbers mean

You'll see CagriSema written as "2.4 mg/2.4 mg." That's not one dose of 4.8 mg. It's two different drugs, each at 2.4 mg:

• Cagrilintide — the first number. This is the new one. It is a long-acting version of amylin, a hormone involved in fullness, food intake, and body-weight control.
• Semaglutide — the second number. You already know this one. It's the drug in Wegovy and Ozempic.

Please don't add them together. They're different molecules that do different things, and calling it "a 4.8 mg dose" is how people end up badly confused about what they're taking.

Why some charts say "week 16" and others say "week 17"

This one causes real arguments online, and both sides can be describing the same timeline.

In trial paperwork, the dose changes happen at study visits: week 0, week 4, week 8, week 12, and week 16. So the paper says the maximum was reached by week 16.

But if you're counting full blocks of treatment, you'd write weeks 1–4 at the starting dose, weeks 5–8 at the next one, and so on. Under that way of counting, the first full week on 2.4 mg/2.4 mg is week 17.

Same timeline. Two ways of writing it down. If you found a chart saying 16 and another saying 17, neither is automatically fake — check how it counts the first dose.

How it was given in the trial

Three facts from the published REDEFINE 1 report:

• Once a week
• Injected under the skin
• A dual-chamber, single-dose, single-use pen — one device holding both drugs, used once

That pen matters more than it sounds like it does. Hold onto it. It comes back later as the reason two separate vials aren't the same thing as CagriSema.

Is the CagriSema dosing schedule FDA approved?

No. As of August 8, 2026, CagriSema is not FDA approved, so there is no official U.S. dosing schedule. Novo Nordisk filed its New Drug Application on December 18, 2025, for the 2.4 mg/2.4 mg fixed-dose injection. The company says it expects a U.S. decision in the fourth quarter of 2026. Every CagriSema dose chart available today describes a study protocol, not an approved prescription label.

Here's where things actually stand:

Novo's "fourth quarter 2026" is the company's expectation, not an FDA promise. Novo has published a quarter, not an exact FDA action date.

What could change when a real label arrives

If the FDA approves CagriSema, the official schedule could differ from the trial chart in any of these ways:

• A different starting dose
• Longer or shorter gaps between steps
• More than one approved maintenance dose
• Rules for delaying or lowering a dose
• Missed-dose instructions
• Who can and can't take it
• A different commercial device

That's not us hedging. Novo has completed a lower-maintenance-dose trial, is running a longer trial with dose re-escalation, has run a tapering extension, and started a high-dose Phase 3 trial in the second quarter of 2026. The full dosing story is still being tested.

The honest problem with waiting for this drug

We're going to be straight with you, because you'll trust everything after this more if we are.

On February 23, 2026, CagriSema went head-to-head against tirzepatide — the drug sold as Zepbound — and lost that test. REDEFINE 4 was an open-label, 84-week trial with 809 people. Under the efficacy estimate, CagriSema produced 23.0% weight loss and tirzepatide produced 25.5%. Under the estimate that counted results whether people stayed on treatment or not, the numbers were 20.2% and 23.6%. CagriSema did not prove it was non-inferior, and both reported estimates favored tirzepatide.

So if you're reading this to decide whether to hold out for CagriSema: the drug that beat it in that trial is already FDA approved and sold now.

But that's exactly why the dosing schedule is the interesting part. REDEFINE 1 let investigators delay or reduce doses. Novo is now testing lower maintenance doses, longer treatment, re-escalation, and a higher-dose combination. That doesn't prove the REDEFINE 4 result was caused by dosing. It proves the company still sees dosing as one of the main questions left to solve.

If you'd rather skip the science and deal with what you can actually get, jump to what to do right now. Otherwise, keep reading — the next three sections are the ones you can't get from a basic dose chart.

Waiting on a drug that isn't approved yet, while your weight isn't waiting? The Find My GLP-1 Path tool takes about 60 seconds and shows which treatment paths are available in your state now — with FDA-approved and compounded paths kept clearly separate and pricing tied to its source.

→ See which treatment paths are available in my state

Why did the CagriSema dose go up every four weeks?

The four-week gaps were used to manage side effects while the dose rose. Gut problems were common in REDEFINE 1: 79.6% of people on CagriSema had at least one gastrointestinal event. Nausea, diarrhea, and vomiting peaked during the climb and eased later. Starting low and moving in four-week blocks gave investigators room to delay or lower the dose when needed.

That's the standard explanation, and it's true. But the cleanest comparison is not a made-up rule about two drugs "adding" their side effects. It is what the four randomized groups actually reported.

What happened in the four REDEFINE 1 groups

REDEFINE 1 did not only test CagriSema. It also tested each half by itself, plus placebo, in the same trial:

• CagriSema, both drugs together: 2,108 people
• Semaglutide alone: 302 people
• Cagrilintide alone: 302 people
• Placebo: 705 people

Source: REDEFINE 1, published in the New England Journal of Medicine. Our comparison places three published outcomes side by side.

The useful pattern is concrete: compared with semaglutide alone, the combination arm had a 5.8-point higher gut-event rate, a 2.3-point higher all-side-effect discontinuation rate, and a 13.5-point lower top-dose rate at week 68.

That does not prove one number caused the next. It does show why dose flexibility was not a footnote. The combination group had more gut events and fewer people still at the maximum dose than either single-drug group.

Novo's FDA filing release also gives the three most common gut-event rates for CagriSema versus placebo: nausea 55.0% versus 12.6%, constipation 30.7% versus 11.6%, and vomiting 26.1% versus 4.1%.

The point is not that CagriSema was unbearable. Most gut events were mild or moderate, and most people were still receiving trial treatment at week 68. The point is that the 16-week ladder was not a command to keep climbing no matter what happened.

Did everyone in the trial reach 2.4 mg/2.4 mg?

No. Three-quarters of people on CagriSema — 74.7% — reached the full 2.4 mg/2.4 mg dose at some point. But 57.4% were on it at week 68. The trial let investigators delay the climb, keep someone at a lower dose, reduce the dose, or pause treatment. That left 42.6% below the maximum assigned dose at week 68.

Those two numbers together tell the real story: most people got to the top. A large minority were not there at the end.

And here's what makes it land. The same trial ran each half of the drug by itself, on the same general four-week ladder:

Same trial. Same visit schedule. Same maximum-dose goal.

At week 68, the combination's top-dose rate was 13.5 percentage points lower than semaglutide alone and 25.1 points lower than cagrilintide alone.

The combination also had the highest rate of stopping treatment because of any side effect: 5.9%, compared with 3.6% on semaglutide and 2.6% on cagrilintide. That still means more than 94% did not stop for that reason. It also means the combination was the hardest active arm to keep at its maximum dose.

What Novo's 2026 dose-reduction analysis added

Novo later published a full poster about the dose reductions. This is the missing piece the first trial paper could not show in one table.

Among 1,101 CagriSema participants with a reduction, investigators made 2,063 dose reductions in total:

• 48% had one reduction
• 29% had two
• 14% had three
• 9% had four or more

The first reduction happened at a mean of week 26 and a median of week 21. About 64% of first reductions happened after the 16-week climb. About 36% happened during it.

At the first reduction:

• Mean weight loss was 14%
• 24.8% had already lost at least 20%
• Mean BMI was 32.1, down from 37.3 at baseline
• 42.8% had a BMI below 30

That supports the idea that strong weight response mattered for some people. But it kills the easy story that every reduction meant "the drug worked too well" or that every reduction was caused by gut trouble.

In the 14 days before the first reduction, 24% had no gastrointestinal event. Investigators judged the most recent gut event as unlikely to be treatment-related for another 31%.

So the honest answer is mixed: dose reductions followed weight loss, tolerability problems, and investigator judgment in different combinations. There was no single reason that explains everyone.

Why the trial allowed dose changes at all

This is the part that flips the whole story, so it's worth saying plainly.

Novo built the flexibility in on purpose, before the trial started. Investigators could delay an increase or reduce the dose when the current dose was tied to side effects, or when a participant reached the lower-normal BMI range and had a health concern. People could stay in the trial at a submaximal dose based on clinical judgment.

The ladder was the plan. It was not a rule that overrode the person.

Did people on lower CagriSema doses really lose more weight?

Yes — but the result does not mean taking less caused more weight loss. In a post-hoc REDEFINE 1 analysis, people who finished below 2.4 mg/2.4 mg had lost 25.2% at week 68. People who finished on the top dose had lost 22.2%. The lower-at-end group was also ahead at week 20: 15.9% versus 12.7%. That tells you the groups were different. It does not prove the lower dose was better.

This is the single most misunderstood fact about this drug, and it took us reading Novo's investor slides line by line to find the number that explains it.

Here it is:

Source: Novo Nordisk Q4 2024 investor presentation, slide 14. This was a post-hoc comparison by end-of-treatment dose, not a randomized dose trial.

Week 20 is four weeks after the planned ladder ends. The later dose-reduction analysis puts the median first reduction at week 21, while 36.2% of first reductions happened during the climb. So week 20 does not prove the lower-at-end group was ahead before every dose change.

It does prove the gap appeared early. The group that would finish lower was already ahead at week 20 — 15.9% versus 12.7%.

They also had more than twice as many gut events per year: 4.0 versus 1.9. And they ended at a lower average BMI: 26.5 versus 30.4.

Novo's footnote says reductions could happen because of gut side effects or a BMI in the lower-normal range. Its 2026 poster shows a broader mix around the reductions.

So here's the sentence that should replace every "lower doses work better" headline:

The dose you end up on can be a result of how your body responds. This comparison does not prove that taking less caused more weight loss.

The lower-at-end group had stronger observed loss, more gut events, and less room before reaching a low BMI. Investigators then made dose decisions. That is selection, not a clean test of which dose works better.

Which means the question people ask — "will I have to get all the way to 2.4?" — is the wrong question. The right one is: "will whoever prescribes this actually adjust it with me?" That's a question about your care, not about chemistry.

But does a lower dose work as well? Here's the actual test

Everything above is a look-back at one trial, and look-backs can mislead. So we went looking for a trial that put two CagriSema doses side by side on purpose.

It exists. REIMAGINE 1 ran CagriSema 2.4 mg/2.4 mg against CagriSema 1.0 mg/1.0 mg and placebo in 189 adults with type 2 diabetes for 40 weeks. The lower arm used an eight-week climb. The higher arm used a 16-week climb.

Sources: the REIMAGINE 1 peer-reviewed record, ClinicalTrials.gov NCT06323174, and Novo's June 2026 results release. Numbers shown use the trial's efficacy estimate.

Now the arithmetic nobody has published in one sentence:

Going from 1.0 mg/1.0 mg to 2.4 mg/2.4 mg means taking 2.4 times as much of each drug. In this trial, the placebo-adjusted mean weight-loss result rose from 10.4 to 12.4 percentage points. That's 2.0 more points, or about 19% more than the lower-dose result after subtracting placebo.

In plain English: in this 40-week diabetes trial, almost two and a half times as much of each drug came with about a fifth more placebo-adjusted mean weight loss.

That's a real trade-off, not a trick. More was more. It was not proportional.

Read this before you run with that number: this was one 40-week trial in 189 adults with type 2 diabetes, not the obesity-only population. Both doses beat placebo, but the trial was not designed to prove the two CagriSema doses were equal or to give people a dose-picking rule. This is a description of what happened, not a reason for anyone to choose a dose on their own.

What other CagriSema doses are being studied?

Four CagriSema dose pairs have been or are being tested in Phase 3: 1.0 mg/1.0 mg, 1.7 mg/1.7 mg, 2.4 mg/2.4 mg, and a high-dose 2.4 mg/7.2 mg combination. Other trials test what happens when treatment lasts longer, a dose is tapered, or a dose is raised again. The FDA application filed in December 2025 is for 2.4 mg/2.4 mg.

Every basic CagriSema page shows you one ladder. Here are the dosing-focused trials and the key comparisons, pulled from Novo's filings and trial registry records.

The CagriSema dose ladder map

Three things jump out of that table.

First: REDEFINE 8 does not use a 12-week climb. Its public record says the climb can last up to 16 weeks. The 12-week schedule belongs to the 1.7 mg/1.7 mg arm in REDEFINE 9. The 1.0 mg/1.0 mg arm uses an eight-week climb.

Second: 2.4 mg/7.2 mg is no longer a mystery label. Novo's own August 2026 financial report says the high-dose trial compares CagriSema 2.4 mg/7.2 mg with CagriSema 2.4 mg/2.4 mg and semaglutide 7.2 mg. That confirms the first number is cagrilintide and the second is semaglutide.

Third: the lower-dose question now has a real Phase 3 result, but not a public number yet. Novo says both 1.0/1.0 and 1.7/1.7 beat placebo in REDEFINE 9. The detailed results are due at a scientific meeting later in 2026. Until those numbers are public, nobody can honestly tell you how close either lower dose came to 2.4/2.4 in the obesity population.

Is there a higher-dose CagriSema?

Yes. Novo started a Phase 3b trial of CagriSema 2.4 mg/7.2 mg in the second quarter of 2026.

The trial compares three groups:

• CagriSema 2.4 mg/7.2 mg
• CagriSema 2.4 mg/2.4 mg
• Semaglutide 7.2 mg

So the higher number is semaglutide. No inference is needed anymore.

Would the climb be longer? The public trial record should decide that, not a guess based on a different drug's label. Until the full high-dose schedule is posted in a clear public protocol, this page will not invent the missing steps.

None of this is available as CagriSema treatment today. The high-dose trial is expected to read out in the first half of 2028.

Four Phase 3 dose pairs, and none is an approved CagriSema prescription today. Rather than tracking a drug you can't get, spend 60 seconds finding out what you can. The Find My GLP-1 Path tool asks about your state, insurance, and preferred form, then shows current paths with prices tied to their source.

→ Get my personalized GLP-1 action plan

Is the CagriSema dosing schedule the same as Wegovy or Zepbound?

No. The first four semaglutide steps in CagriSema match the familiar Wegovy injection ladder: 0.25, 0.5, 1.0, and 1.7 mg in four-week blocks. But CagriSema adds cagrilintide, has no approved label, and no rule from the Wegovy or Zepbound label automatically carries over to it.

Sources: current Wegovy prescribing information and current Zepbound FDA label, checked August 8, 2026.

A current detail many old comparison pages miss: Wegovy's U.S. injection label now includes a 7.2 mg maximum for some adults who have tolerated 2.4 mg for at least four weeks and need more weight reduction. That does not turn Wegovy's rules into CagriSema rules.

Don't compare the milligrams across drugs. 2.4 mg of semaglutide and 15 mg of tirzepatide are different molecules. A bigger number doesn't mean a stronger drug. Compare the schedules, outcomes, approved uses, and tolerability — not the printed milligrams.

And one thing that matters practically: you cannot borrow Wegovy's or Zepbound's missed-dose instructions for CagriSema. No approved CagriSema label exists, so no official CagriSema missed-dose rule exists. Anyone in a trial should call the study team.

What about cagrilintide by itself?

Cagrilintide alone isn't CagriSema. It's a separate investigational drug that Novo is developing on its own track. In REDEFINE 1 it produced 11.8% mean weight loss under the trial-product estimate, against 22.7% for the combination. It's also not FDA approved, and its own future dosing rules would not transfer to the combination.

What do online CagriSema dose charts get wrong?

Most bad charts start with one true row of numbers and then add claims the trial never supported — faster step-ups, weight loss promised by week, missed-dose rules, instructions for combining separate products, or vial math. A correct ladder does not make the advice around it safe or true.

Use this fact-check table before you trust a chart:

Match a chart to the trial it probably came from

This is the fastest way to tell whether two real-looking charts are describing the same study:

A chart can be real and still be wrong about which study it describes. Ask for the NCT number. If the page cannot name the trial, do not let the neat table fool you.

Can you get CagriSema now, or put it together yourself?

No FDA-approved CagriSema product is available by prescription in the United States. FDA states that cagrilintide cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition. There is no lawful U.S. commercial prescription or cagrilintide-compounding route that turns a seller's vial into CagriSema. For a person seeking CagriSema today, the verifiable regulated access route is a registered clinical trial.

We're going to explain this carefully, because a lot of people reach this page after seeing a vial for sale.

What the FDA actually says

The FDA's page on unapproved GLP-1 drugs is short and direct on this point. Cagrilintide cannot be used in compounding under federal law. It isn't a component of an approved drug. And it hasn't been found safe and effective for anything.

That's not a gray area a seller can work around. "Compounded CagriSema" is not a lawful federal compounding category.

Why two separate drugs aren't CagriSema

Remember that dual-chamber pen? Here's why we asked you to hold onto it.

The product studied in Phase 3 was a fixed-dose combination in a dual-chamber, single-dose, single-use pen. One device. Both drugs. Fixed amounts. Made under the controls used for a clinical trial product.

Two separate vials from two sources are not that product. Different formulation. Different manufacturing controls. Different stability questions. No reliable way for a buyer to confirm what is inside. A matching milligram number on a label doesn't make two things the same.

Worth knowing: the earlier Phase 2 obesity trial did give the two drugs as separate injections. So both "co-administered" and "fixed-dose combination" appear in the research, and they mean different things. The Phase 3 product behind the FDA filing was the fixed-dose pen.

Red flags on a page selling this

If you're looking at a seller right now, these are the tells:

• "Research use only" followed by human dosing directions
• A calculator for mixing or measuring
• Instructions in syringe units
• "No prescription needed"
• Purity claims with no verifiable lot testing and chain of custody
• Any claim of being equivalent to Novo's product
• Weight loss promised by week
• Advice to move up faster than the trial did
• No licensed prescriber or identifiable pharmacy anywhere on the page

The one thing a vial can't give you

This is the honest heart of it, and it costs us nothing to say.

The most important part of CagriSema's dosing schedule isn't the ladder. It's the permission to come off it.

Go back and look at the 2026 dose-reduction data. Some first reductions followed large weight loss. Some followed gut trouble. Some happened without a recent gut event. Investigators used a person's response, BMI, symptoms, and health concerns to make the call.

There's no version of that in a vial. The ladder is the easy part to copy. The judgment isn't.

And the 25.2% result in the lower-at-end subgroup does not belong to a vial seller. It came from a monitored trial with scheduled visits and investigator-directed changes.

If you want to be in a trial

That's a real option. Search ClinicalTrials.gov by the NCT numbers in the trial map. Some CagriSema studies are active but no longer recruiting; others may add or change sites. The study supplies the protocol treatment and monitoring. Ask the site what it covers and whether travel or other costs are reimbursed before you enroll.

What should you do right now?

One FDA-approved weekly injection beat CagriSema in the REDEFINE 4 head-to-head trial. Under the efficacy estimate, tirzepatide 15 mg produced 25.5% mean weight loss over 84 weeks compared with 23.0% for CagriSema. The trial did not prove CagriSema was non-inferior. You do not have to wait for an investigational drug to talk with a licensed clinician about approved options.

Find yourself below.

If you're in a CagriSema trial

Follow your study team's instructions, not this page. Call your coordinator about a missed dose or a side effect. Nothing here overrides your protocol.

If you already bought a vial

Don't use our chart to work out an amount. That's the whole reason we didn't publish measurement math. Talk to a licensed clinician about approved options. Keep the seller's name, website, receipt, lot details, and messages in case you need to report the product.

If you've plateaued on a GLP-1

You're close to the question Novo is testing. REDEFINE 11 studies longer treatment and later dose levels. The high-dose 2.4/7.2 trial tests whether more semaglutide adds benefit. REDEFINE 11 is expected to report in the first half of 2027; the high-dose trial is expected in the first half of 2028.

In the meantime, the honest moves are the boring ones: talk to your prescriber about whether your current approved dose is optimized and whether switching treatments makes sense. Our guide on lean mass loss by drug covers what to protect while you do it.

If you haven't started yet

Don't wait for CagriSema. Tirzepatide is FDA approved now. Semaglutide is FDA approved now. The right choice depends on your health history, what your plan covers, the approved indication, cost, supply, and what you can tolerate.

If the drug that beat CagriSema is the one you want

Here's the practical part. Getting Zepbound or Wegovy often comes down to whether your plan covers it, whether prior authorization is required, and whether you need a new prescriber.

Ro offers a free coverage check for select branded GLP-1 drugs and says its insurance concierge handles the paperwork. The membership and medication are separate charges.

Ro price verification — August 8, 2026

Sources checked: Ro pricing and NovoCare Wegovy pricing. Prices can change. Check the source again before paying.

Ro's honest limitation: it is not the cheapest route when all you need is a cash prescription you already have. Ro says its cash medication prices match manufacturer-direct programs, but Ro adds a membership fee. If you already have a clinician writing the prescription and price is your only concern, check NovoCare for Wegovy or the current manufacturer channel for Zepbound before paying for a membership.

What the membership buys is the part a cash-only pharmacy does not: a prescriber pathway, a coverage check, prior-authorization help, messaging, check-ins, and ongoing care. That can matter if paperwork or access is the thing stopping you.

This CTA is for the FDA-approved branded paths listed on Ro's page. It is not a route to CagriSema.

→ Check your insurance coverage free on Ro (affiliate link)

Not sure Ro fits? Read our full breakdown at Ro Body reviews, including exactly where manufacturer-direct can be cheaper.

On the record: what the people running these trials have said

We don't have an approved CagriSema customer base to quote. A post about "my CagriSema results" could come from a trial participant or from someone who bought a gray-market product. It is not proof from an approved commercial treatment, and we won't use it as sales copy.

What we can use is the public record from the people running the program.

Martin Holst Lange, Novo Nordisk's chief scientific officer, said after REDEFINE 4 that Novo was looking to REDEFINE 11 and the higher-dose trial to test CagriSema's full weight-loss potential. That is the company's framing, not an independent verdict. It also tells you why this page does not pretend the final dose question is settled.

Dr. W. Timothy Garvey of the University of Alabama at Birmingham, the lead REDEFINE 1 author, reported that the protocol let investigators delay escalation or reduce the dose for side effects or a lower-normal BMI with a health concern. The 2026 poster then showed how varied those reductions were in real participants.

Both records point the same direction, and it's the direction this whole page has been walking: the schedule was built to be adjusted inside a trial.

Disclosure: Dr. Garvey has served as a consultant and trial investigator for Novo Nordisk and several competitors. Mr. Lange is a Novo Nordisk executive.

What people are actually asking about CagriSema dosing

Short answers to the questions people ask in their own words.

"Do I have to get to the full 2.4 mg dose?" In REDEFINE 1, not everyone did. 74.7% reached it at some point, and 57.4% were on it at week 68. That was a flexible trial protocol, not an approved patient rule.

"How long is the titration?" Sixteen weeks in the main REDEFINE 1 trial. The maximum was reached at the week-16 visit, so the first full week at 2.4 mg/2.4 mg is week 17.

"Can I add cagrilintide to my semaglutide prescription?" No lawful U.S. compounding route exists for that. FDA says cagrilintide cannot be used in compounding under federal law, and the Phase 3 product was a fixed-dose dual-chamber pen.

"Is CagriSema stronger than Zepbound?" That is not a clean way to compare drugs. In the only obesity head-to-head trial, both reported mean weight-loss estimates favored tirzepatide, and CagriSema missed the non-inferiority goal.

"What's the starting dose?" In REDEFINE 1, 0.25 mg of cagrilintide plus 0.25 mg of semaglutide, once a week.

"Will there be a higher dose?" A Phase 3b trial of 2.4 mg/7.2 mg started in the second quarter of 2026 and is expected to report in the first half of 2028.

"Why do two charts I found not match?" They may count week 16 and week 17 differently, or they may describe different trials. The 1.0/1.0 lower-dose arms use an eight-week climb. REDEFINE 9's 1.7/1.7 arm uses 12 weeks. REDEFINE 1 and REDEFINE 8 use 16 weeks.

How we built this page

Every dose number here comes from a Novo Nordisk document, a peer-reviewed trial report, an FDA document, or a clinical trial registry record. The calculations are ours, and we've shown the inputs so you can check them. Where a result is post hoc or a comparison is descriptive rather than a randomized dose test, we say so in that section.

Primary source ledger

• REDEFINE 1 results, New England Journal of Medicine 2025;393:635–647 — trial design, fixed-dose pen, 16-week climb, 74.7%, 57.4%, group sizes, safety, and discontinuation
• ClinicalTrials.gov NCT05567796 — correct REDEFINE 1 registry record
• Novo Nordisk 2026 REDEFINE 1 dose-reduction poster — 2,063 reductions, timing, weight loss, BMI, and recent gut-event pattern
• Novo Nordisk Q4 2024 investor presentation — post-hoc end-of-treatment dose comparison
• Novo Nordisk's February 23, 2026 SEC filing — REDEFINE 4 design, both weight-loss estimates, failed non-inferiority endpoint, and selected trial descriptions
• Novo Nordisk's December 18, 2025 CagriSema filing announcement — NDA date, filed dose, indication, and source trial program
• Novo Nordisk Q2 2026 investor presentation — Q4 decision expectation, REDEFINE 9 completion, REDEFINE 11 start, and high-dose start
• Novo Nordisk Q2 2026 financial report — lower-dose result direction, confirmed 2.4/7.2 composition, comparator arms, and expected high-dose readout
• REIMAGINE 1 peer-reviewed record, NCT06323174, and Novo's June 2026 results release — randomized 1.0/1.0, 2.4/2.4, and placebo results
• REDEFINE 8, NCT06780449 — 16-week escalation and tapering extension
• REDEFINE 9, NCT06388187 — 1.0/1.0 and 1.7/1.7 lower-dose schedules
• REDEFINE 11, NCT07011667 — longer main phase and extension dose levels
• High-dose trial, NCT07564414 — public high-dose Phase 3b record
• FDA, “FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” — cagrilintide and federal compounding status
• Current Wegovy prescribing information — current injection ladder, maintenance choices, 7.2 mg option, and missed-dose rules
• Current Zepbound FDA label — starting dose, escalation, maintenance doses, maximum, and missed-dose rules
• Ro pricing and NovoCare Wegovy pricing — current prices and offer limits checked August 8, 2026

What we calculated ourselves: the 42.6% below-maximum figure, the top-dose gaps between groups, the drop from ever reaching maximum to being on maximum at week 68, the cross-outcome comparison in the safety table, the 42.8% below-BMI-30 figure at first reduction, the post-hoc subgroup comparison, and the placebo-adjusted dose-efficiency arithmetic from REIMAGINE 1.

What we did not do: publish measurement or mixing instructions, recommend a dose, build a dose calculator, tell anyone to change how much they take, borrow missed-dose rules from a different product, or use gray-market posts as proof.

What remains unknown: the FDA decision, the approved CagriSema label, final commercial device, official missed-dose rules, price, coverage, and launch timing. REDEFINE 9's detailed obesity results are also not public yet.

One thing you should weigh: the REDEFINE and REIMAGINE programs were designed, funded, and analyzed by Novo Nordisk. The dose-reduction poster was sponsored by Novo. Every efficacy number on this page comes, in the end, from the company developing the drug or from a trial it funded. That's normal in drug development. It's still worth knowing.

Found something we got wrong, or a status change after August 8, 2026? Send us the original document — not a copied chart — and we'll recheck the whole page before we touch the verification date.

CagriSema dosing schedule FAQ

Is CagriSema FDA approved? No. Novo Nordisk filed its application on December 18, 2025, and says it expects a U.S. decision in the fourth quarter of 2026. No FDA-approved CagriSema label exists as of August 8, 2026.

What was the starting dose in the trial? 0.25 mg of cagrilintide plus 0.25 mg of semaglutide, once a week under the skin.

What is the CagriSema maintenance dose? There is no approved maintenance dose. In REDEFINE 1 and REDEFINE 2, the target was 2.4 mg of each drug once a week. REDEFINE 9 has completed testing 1.0 mg/1.0 mg and 1.7 mg/1.7 mg. Detailed results are not public yet.

How many weeks is the climb? Sixteen weeks in REDEFINE 1. REDEFINE 9 used eight weeks for 1.0/1.0 and 12 weeks for 1.7/1.7. REDEFINE 8 used up to 16 weeks.

When does the 2.4 mg/2.4 mg dose start? The dose change happens at the week-16 trial visit, which means the first full week on it is week 17. Charts saying "16" and "17" can describe the same timeline.

Do both drugs go up at the same time? In REDEFINE 1, yes. The fixed combination increased both components together.

Did everyone reach the full dose? No. 74.7% got there at some point; 57.4% were on it at week 68.

What if someone couldn't handle a dose increase? In REDEFINE 1, investigators could delay escalation, lower the dose, or interrupt treatment. That was investigator-directed, not a rule anyone can apply alone. There's no approved CagriSema label with dose-adjustment instructions.

Is CagriSema one injection or two? The Phase 3 product behind the FDA filing was one fixed-dose, dual-chamber, single-use pen. An earlier Phase 2 obesity trial gave the two drugs as separate injections, which is why both descriptions appear in the research.

What's the highest CagriSema dose being studied? 2.4 mg of cagrilintide plus 7.2 mg of semaglutide in a Phase 3b trial started in the second quarter of 2026.

Can a pharmacy compound CagriSema? No lawful federal compounding route exists for cagrilintide. FDA states that cagrilintide cannot be used in compounding under federal law.

Does CagriSema come as a pill? No approved CagriSema product exists. The Phase 3 programs covered here use injections under the skin.

What should someone do after a missed dose? There is no official CagriSema missed-dose instruction because there is no approved label. Anyone in a trial should call the study team rather than borrow rules from Wegovy or Zepbound.

Is 2.4 plus 2.4 the same as a 4.8 mg dose? No. They're two different drugs, each at 2.4 mg. Write it as 2.4 mg/2.4 mg.

The bottom line

The CagriSema dosing schedule in the main trial is straightforward: 0.25 mg of each drug to start, up a step every four weeks, with the 2.4 mg/2.4 mg target reached at the week-16 visit. One shot a week. Both drugs rise together.

What the chart doesn't tell you is the interesting part. Three-quarters of people reached the top at some point. At week 68, 57.4% were on it and 42.6% were not. The lower-at-end subgroup lost more, but that was a post-hoc comparison shaped by response, side effects, BMI, and investigator decisions — not proof that a lower dose works better.

There are four CagriSema dose pairs in Phase 3, not one. The drug's own maker is still testing lower maintenance doses, longer treatment, re-escalation, and a high dose. And in the meantime, the FDA-approved drug that beat it in the obesity head-to-head trial is available now.

That's not a sad ending. It means you don't have to wait for anything.

Still not sure which GLP-1 path fits your state, insurance, and budget? Take our free 60-second matching quiz.

→ Find My GLP-1 Path

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost. Independent guidance for choosing your GLP-1 path.

This article is for information only and is not medical advice. It does not recommend a dose of any medication. CagriSema is an investigational drug that is not approved by the FDA and is not available as an approved prescription product. Talk to a licensed clinician about treatment options that are available to you.

Related reading: GLP-1 Clinical Trials Tracker · Compounded GLP-1 Enforcement Tracker · GLP-1 Lean Mass Loss by Drug · Ro Body Reviews